Why the Competition Commission’s decision on two cancer medicine cases could have much wider implications
There is a history of competition law being used to drive HIV medicine prices lower in South Africa. Now, two cases involving cancer medicines seem set to nail down what qualifies as “excessive pricing” in South African law – a legal development that could have far reaching implications for medicines prices in the country. Catherine Tomlinson unpacks the details.
